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Introduction
•

BRPC and LAPC have poor prognosis
in which surgery is the only curative
treatment

Methods
•
•
•
•
•
•

•
•

RT has a controversial role for BRPC
and LAPC, with negative and positive
data in recent years
A high biologically effective dose of RT
is required to achieve tumor ablation

•

Conducted a retrospective study to analyze patients who received chemotherapy
followed by RT for BRPC or LAPC between 2015 and 2020
Patients evaluated as a subset from a larger cohort of 454 patients
RT dates and lowest absolute lymphocyte counts (ALC) during RT periods were
extracted from medical records
CA19-9 normalization = minimum CA19-9 value between the start of chemo and 6
months post-chemo < 40 U/mL
Lymphopenia grade >2 = patient ALC fell below 0.5 K/uL during radiation
Associations between variables were tested using Log-rank and Wilcoxon survival
analyses
Variables with a p value of <.2 in univariate analysis were used in a multivariate Cox
Proportional Hazard survival analysis test to further determine significance

Fig 5. Survival plot for CA19-9 normalizers compared to nonnormalizers.

Results

Variable

CA19-9
Normalization

•
•

Surgery or No
Surgery?

Since RT can impact the nearby
gastrointestinal tract, the use of
curative doses is constrained
Previous studies have shown that RT
following chemo is associated with
better overall survival (OS)

Radiation
Type

Fig 2. Survival plot for different radiation types.

Primary Aims
•

There is an unmet need to identify
biomarkers to select subpopulations
of patients with BRPC and LAPC for
RT

•
Fig 1. Workflow showing how the data set of N = 233 was created
along with the number of patients within each subset of tumor type
and CA19-9 normalization.

CA19-9
Normalization

Non-normalizers
Receive Surgery?

•

•

Norm: 0.489 (0.318-0.745)
Non: 2.04 (1.33-3.14)

0.00012

Surgery: 0.190 (0.106-0.342)
No surgery: 5.25 (2.93-9.42)

0.0001

IMRT: 0.496 (0.279-0.883)
SBRT: 0.359 (0.183-0.703)
VMAT: 0.402 (0.237-0.680)
3-D Plan: 2.49 (1.47-4.21)

0.0032

Conclusions

Variable

Prior results indicated that CA19-9
response and lymphopenia grade
associate with outcomes after RT
Here, we investigated these markers
and other clinical factors to identify
biomarkers that may aid the decision
to use RT for BRPC and LAPC
We hypothesized that lymphopenia
grade and CA19-9 normalization
would show to be independent
predictors of OS

P-value

Table 2. The above three variables showed to be significant (p<.05) in
the multivariate Cox Proportional Hazard Model.

•
•

•

Hazard Ratio
(95% Confidence Interval)

Radiation Type

Tumor Type
(Lymphopenia
grade>2)

Median OS (months)
Normalizer = 19.3
Non-normalizer = 11.5

Surgery = 25.4
No surgery = 8.84
Stereotactic Body RT: 22.7
Volumetric Modulated Arc Therapy:
19.1
3-D Plan: 11.5
Intensity-Modulated RT: 10.1

BRPC: 23.4
LAPC: 11.6

p-value

Fig 3. Survival plot for non-normalizers surgery vs non-surgery
(0 = no surgery, 1 = surgery).

•

0.015

0.0001

References

0.019

0.003

Table 1. The above four variables showed to be significantly associated
with overall survival in the patient population (p<.05). Log-rank and
Wilcoxon tests were used to evaluate significance.

Preliminary analysis indicated CA19-9
to be a significant variable associated
with OS as predicted
Lymphopenia grade did not show to be
significant as an independent variable
However, there was a significant
difference in BPRC vs LAPC OS for
patients with lymphopenia grades >2
Additional prospective trials are
needed to evaluate the ability of these
factors to personalize treatment and
solidify stable biomarkers

Fig 4. Survival plot for different tumor types of patients with
lymphopenia grade >2.
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